Alto Neuroscience Inc

ANRO

Company Profile

  • Business description

    Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

  • Contact

    650 Castro Street
    Suite 450
    Mountain ViewCA94041
    USA

    T: +1 650 200-0412

    https://www.altoneuroscience.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    76

Stocks News & Analysis

stocks

Ask the analyst: Are markets missing something with CSL?

I catch up with Shane Ponraj after an eventful reporting season for healthcare major CSL.
stocks

This ASX stock’s bubble has well and truly burst

Pandemic related tailwinds are a distant memory for Reece, which looks set to face more competition in Australia.
stocks

Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026

Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,216.5012.00-0.13%
CAC 407,709.81133.23-1.70%
DAX 4024,152.87120.25-0.50%
Dow JONES (US)45,418.07135.600.30%
FTSE 1009,265.8055.60-0.60%
HKSE25,524.92304.99-1.18%
NASDAQ21,544.2794.980.44%
Nikkei 22542,352.9541.45-0.10%
NZX 50 Index12,910.7647.22-0.36%
S&P 5006,465.9426.620.41%
S&P/ASX 2008,949.7011.50-0.13%
SSE Composite Index3,868.3815.18-0.39%

Market Movers